PubMed Health⌕ Search

Biomedical subjects

Jérome Guiramand

Publications and source records attributed to Jérome Guiramand.

6 recordsLinked to original sources
PubMed2006

Perineal small bowel fistula after pelvic exenteration for cancer: technical guidelines for perineal fistula.

BACKGROUND: To determine guidelines for the management of perineal small bowel fistula (PSF) after total or posterior pelvic exenteration. METHODS: During 15 years, 315 curative pelvic exenterations were performed. PSF occurred in 15 patients (3.5%). We retrieved the precise modality of radiotherapy (fields and doses) and management of all patients (type of surgery, number of surgery and mortality). Delay of occurrence was divided in early (within 30 days or before hospital discharge) and delayed. RESULTS: All patients underwent surgery. Mortality rate was 13%. Fourteen patients (93%) had history of radiotherapy. No PSF was noted after anterior pelvic exenteration. Higher frequency of PSF was noted after total pelvic exenteration versus posterior pelvic exenteration (P = 0.04). Early PSF occurred in four patients (27%) with higher frequency of small bowel intraoperative injury. Late PSF occurred in 11 patients (73%) divided in small bowel injury in contact with pelvic staples (n = 4) and disease recurrence (n = 6, local recurrence or carcinomatosis). One patient had delayed PSF by ulceration of small bowel in contact with pelvic drain. CONCLUSION: PSF was a life-threatening complication of pelvic exenteration. Radiotherapy leads to weaken small bowel with difficulty of cicatrisation. During pelvic exenteration: (a) extreme careful dissection and interposition of great omentum could avoid small bowel injury, (b) control of pelvic vessels and closure of rectum remnant should not used staplers. Intraoperative management of PSF used successful simple repair in case of early PSF or segmentary resection indeed enlarged to right colon in case of delayed PSF. Postoperative courses had to use intravenous hyperalimentation and digestive tract discharge.

Female↗
PubMed2006

Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour.

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal tumours of the gastrointestinal tract. Most of them have an activating mutation of KIT or PDGFRalpha tyrosine-kinase receptors. Imatinib is a selective tyrosine-kinase inhibitor of ABL, KIT and PDGFR, and provides a clinical benefit in about 85% of patients with advanced GIST. Unfortunately, secondary resistance following initial responses occurs in most of the cases, and molecular mechanisms are poorly understood. We sequenced KIT and PGDFRalpha exons from one patient with GIST before and after the development of imatinib resistance. We identified, in addition to a primary mutation in exon 9, a secondary mutation in KIT exon 13 (first kinase domain) in the resistant sample. We demonstrate for the first time the feasibility of sequencing such samples removed by non-surgical biopsies during imatinib therapy. Such a approach, far less invasive than surgery and combined with sequencing, will likely help in better tailoring the treatment of advanced GISTs and understanding the mechanisms of resistance and response to imatinib.

Antineoplastic Agents↗
PubMed2005

Long-term follow-up of continent urinary diversion after pelvic exenteration for gynecologic malignancies.

OBJECTIVE: The objective of this retrospective study was to analyze the long-term outcome of patients undergoing a continent urinary diversion (UD) at the time of pelvic exenteration (PE). PATIENTS AND METHODS: Between February 1993 and January 2001, 60 PE for gynecologic malignancies and requiring a UD were performed. Patient's preference, type of UD planned, type of UD performed, and late urinary morbidity (after day 90) were analyzed. RESULTS: Eighty-two percent of the entire group (49/60) matched preoperatively criteria to have a continent UD and 41 continent UD were eventually performed (87%). Postoperative mortality in patients with a continent UD was 4.9% (2/41) and wasn't related to urinary complications. After a 20-month median follow-up, 18 patients (46%) with a continent UD developed late complications directly UD-related. These complications were: (a) major in 28% (5/18) requiring re-operation in 3 cases or endoscopic treatment in 2 cases; (b) minor in 72% (13/18) constantly medically treated. Chronic diarrhea was more frequent in patient who had small bowel or left colon resection (P < 0.05) and urine leakage was more frequent in patient with higher BMI (P < 0.05). At last follow-up, no patient had stopped self-catheterizations or asked for undiversion. CONCLUSIONS: In our experience, continent UD at the time of PE despite high acceptability and feasibility rate, appeared to be strongly related to specific late complications, uncommon with ileal conduit. However, these complications remained more frequently minor and could be treated safely and conservatively.

Female↗
PubMed2004

Assessment of pathologic response after preoperative chemoradiotherapy and surgery in pancreatic adenocarcinoma.

PURPOSE: The benefits provided by preoperative chemoradiotherapy (CRT) in pancreatic ductular adenocarcinoma (PDA) are still controversial. However, in most reports from referral centers, improvement in local control and survival appears to be provided in selected patients. The aim of this retrospective study was to analyze the radiation-induced pathologic effects of preoperative CRT in patients with resectable PDA and determine the precise long-term outcome of the responding patients. METHODS AND MATERIALS: Between November 1996 and October 2003, 61 patients underwent preoperative CRT for resectable PDA. The tumor location was the pancreatic head in 49 patients and pancreatic body in 12 patients. Of the 61 patients, 21 (34.5%) did not undergo surgery because of disease progression and 40 (65.5%) underwent pancreatic resection, including pancreaticoduodenectomy in 32 (80%) and distal pancreatectomy in 8 (20%). RESULTS: A major pathologic response was noted in 9 patients, including three complete responses, and was found only in patients with tumor of the pancreatic head. The local control rate was similar in patients with and without a major pathologic response. Survival in patients with a major response was significantly greater than in those without a response or with a minor response. CONCLUSION: Major tumor downstaging can be provided by preoperative CRT in patients with resectable cephalic PDA. Survival appears to be significantly improved in selected patients.

Adult↗
PubMedDate not supplied

Preoperative systemic chemotherapy does not modify strategy of liver resection.

BACKGROUND/AIMS: Most patients who undergo surgical resection of colorectal liver metastases have been previously treated with chemotherapy as adjuvant therapy or as a primary treatment. The aim of this retrospective study was to compare morbidity, mortality, liver function and histology of the liver specimens in patients undergoing colorectal liver metastases (CRLM) resection with and without a history of previous chemotherapy. METHODOLOGY: Records of 210 patients who underwent CRLM resection in our institution between January 1996 and March 2003 were retrospectively reviewed. We selected for further analysis medical charts of 40 patients who didn't receive a combined treatment concurrently to liver resection. Group I included 25 patients who did not receive adjuvant chemotherapy. Group II included 15 patients who received chemotherapy in the 3 months before liver resection. RESULTS: Postoperative mortality was 0% and 0.7% in group I and II respectively. Specific liver complications and pulmonary complications were similar in the two groups: 20% and 32% us. 33% respectively. The mean length of stay in the hospital was similar in the two groups (19 +/- 14 vs. 14 +/- 8). Changes of liver function test were similar in the two groups. Pathologic examination of liver specimens was not different in the two groups. CONCLUSIONS: Preoperative systemic chemotherapy didn't increase the risk of liver resection.

Antineoplastic Agents↗